ReviewFrontiers in oncology2026
Insight into the emerging role of long non-coding RNAs in BRAF inhibitor resistance in melanoma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is the deadliest type of skin cancer, arising from melanocytes, and its global incidence continues to rise. Although multiple somatic mutations contribute towards melanoma development, but the BRAF mutation is the most prevalent. The FDA approval of targeted therapies for BRAF-mutant melanoma greatly increased overall survival in considerable number of patients. However, the majority of patients eventually developed resistance against BRAF inhibitors (BRAFi) and the underlying mechanisms still under explorations. Recent research has revealed that long noncding RNAs (lncRNAs) are closely linked to the development and progression of several malignancies, including melanoma. However, the connection between lncRNA expression profiles and acquired resistance to melanoma BRAFi is in the early stages of research. Herein, we present a current summary of the ways by which lncRNAs either restore melanoma cell susceptibility to BRAFi or cause resistance. Additionally, we have also discussed the potential of lncRNAs role as prognostic indicators of response and resistance to BRAFi therapy in melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.